Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Why Is DexCom (DXCM) Stock Rocketing Higher Today
Why Is DexCom (DXCM) Stock Rocketing Higher Today
Why Is DexCom (DXCM) Stock Rocketing Higher Today
Anthony Lee
Sat, February 14, 2026 at 1:31 AM GMT+9 2 min read
In this article:
DXCM
+7.59%
What Happened?
Shares of medical device company DexCom (NASDAQ:DXCM) jumped 7.3% in the morning session after it reported better-than-expected fourth-quarter 2025 financial results, beating analyst estimates for both revenue and earnings.
The company announced quarterly revenue of $1.26 billion, up 13.1% from the previous year. Its adjusted earnings per share came in at $0.68, surpassing the prior year’s figure of $0.45 and topping Wall Street’s forecasts. While DexCom’s revenue and earnings surpassed expectations, the company’s full-year revenue guidance was in line with analyst estimates. The positive investor reaction suggests a focus on the strong quarterly performance and profitability growth.
Is now the time to buy DexCom? Access our full analysis report here, it’s free.
What Is The Market Telling Us
DexCom’s shares are quite volatile and have had 15 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 4 months ago when the stock dropped 14.8% on the news that the company reported underwhelming earnings.
The company’s revenue grew over 21% year-on-year to $1.21 billion, and its adjusted earnings per share of $0.61 also came in ahead of consensus estimates. DexCom lifted its full-year 2025 revenue forecast to approximately $4.64 billion. Despite these positive metrics, the stock’s decline suggests investors were anticipating an even more robust performance and a more substantial guidance increase. The market’s negative reaction indicates that the strong quarter was not enough to meet the high expectations priced into the stock, prompting a sell-off.
DexCom is up 5.1% since the beginning of the year, but at $69.94 per share, it is still trading 22.9% below its 52-week high of $90.75 from February 2025. Investors who bought $1,000 worth of DexCom’s shares 5 years ago would now be looking at an investment worth $691.86.
Microsoft, Alphabet, Coca-Cola, Monster Beverage—all began as under-the-radar growth stories riding a massive trend. We’ve identified the next one: a profitable AI semiconductor play Wall Street is still overlooking.Go here for access to our full report, it’s free.
Terms and Privacy Policy
Privacy Dashboard
More Info